Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective

References

• Coebergh JW, Reedijk AM, de Vries E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. report from the automated childhood cancer information system project. Eur J Cancer. 2006;42(13):2019–2036. doi:10.1016/j.ejca.2006.06.005
   PubMed Web of Science ®Google Scholar
• Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103. doi:10.3322/caac.21219
   PubMed Web of Science ®Google Scholar
• CANCER.ORG. How is childhood leukemia classified?; 2020. Available from: https://www.cancer.org/cancer/leukemia-in-children/detection-diagnosis-staging/how-classified.html. Accessed April 20, 2022.
   Google Scholar
• Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015;26(11):1627–1642. doi:10.1007/s10552-015-0657-6
   PubMed Web of Science ®Google Scholar
• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663–1669. doi:10.1200/JCO.2011.37.8018
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM study group. Blood. 2000;95(11):3310–3322.
   PubMed Web of Science ®Google Scholar
• Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a children’s oncology group study. Leukemia. 2008;22(12):2142–2150. doi:10.1038/leu.2008.251
   PubMed Web of Science ®Google Scholar
• Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic advances in childhood leukemia consortium study. J Clin Oncol. 2010;28(4):648–654. doi:10.1200/jco.2009.22.2950
   PubMed Web of Science ®Google Scholar
• Reismuller B, Peters C, Dworzak MN, et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J Pediatr Hematol Oncol. 2013;35(5):e200–4. doi:10.1097/MPH.0b013e318290c3d6
   PubMed Web of Science ®Google Scholar
• Ceppi F, Duval M, Leclerc J-M, et al. Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy. PLoS One. 2016;11(9):e0160310. doi:10.1371/journal.pone.0160310
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Volzke E, Kuhl JS, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM study group. Eur J Cancer. 2011;47(1):90–97. doi:10.1016/j.ejca.2010.09.020
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase i/phase ii study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381–4389. doi:10.1200/JCO.2016.67.3301
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Guerin A, Gauthier G, et al. Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant. Int J Hematol Oncol. 2016;5(2):63–75. doi:10.2217/ijh-2016-0001
   PubMedGoogle Scholar
• Hanson SBaSG. 2014 U.S. organ and tissue transplant cost estimates and discussion; 2020. Available from: https://us.milliman.com/en/Insight/2014-usorgan-and-tissue-transplant-cost-estimates-and-discussion. Accessed April 20, 2022.
   Google Scholar
• Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316–322. doi:10.1016/j.bbmt.2007.12.493
   PubMed Web of Science ®Google Scholar
• Dalle JH, Balduzzi A, Bader P, et al. Allogeneic stem cell transplantation from hla-mismatched donors for pediatric patients with acute lymphoblastic leukemia treated according to the 2003 bfm and 2007 international bfm studies: impact of disease risk on outcomes. Biol Blood Marrow Transpl. 2018;24(9):1848–1855. doi:10.1016/j.bbmt.2018.05.009
   PubMed Web of Science ®Google Scholar
• Dalle JH, Balduzzi A, Bader P, et al. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transpl. 2021;56(1):257–266. doi:10.1038/s41409-020-01014-x
   PubMed Web of Science ®Google Scholar
• Balduzzi A, Dalle JH, Wachowiak J, et al. Transplantation in children and adolescents with acute lymphoblastic leukemia from a matched donor versus an hla-identical sibling: is the outcome comparable? Results from the international bfm all sct 2007 study. Biol Blood Marrow Transpl. 2019;25(11):2197–2210. doi:10.1016/j.bbmt.2019.07.011
   PubMed Web of Science ®Google Scholar
• Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33(11):1265–1274. doi:10.1200/JCO.2014.58.9747
   PubMed Web of Science ®Google Scholar
• Novartis. Novartis receives approval for Kymriah® (tisagenlecleucel) by health sciences authority as Singapore’s first commercially approved CAR-T therapy. Available from: https://www.novartis.com.sg/news/media-releases/novartis-receives-approval-kymriah-tisagenlecleucel-health-sciences-authority.Accessed March 2021.
   Google Scholar
• Clinicaltrials.gov. Determine efficacy and safety of ctl019 in pediatric patients with relapsed and refractory b-cell all and high risk b-cell all at first relapse. Determine feasibility and safety of ctl019 therapy in pediatric patients with high risk b-cell all that relapsed < 6 months post all-hsCT. (ELIANA). Available from: https://clinicaltrials.gov/ct2/show/study/NCT02435849. Accessed June 15, 2020.
   Google Scholar
• Dourthe M. Safety and efficacy of tisagenlecleucel (CLTl019) in B acute lymphoblastic leukemia in children and young adults: Rrobert Debré and Saint Louis hospitals experience. Presented at: HemaSphere; 2019; Amsterdam, The Netherlands: EHA. Available from: https://library.ehaweb.org/eha/2019/24th/267244/andre.baruchel.safety.and.efficacy.of.tisagenlecleucel.28ctl01929.in.b.acute.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3. Accessed April 20, 2022.
   Google Scholar
• Dourthe M. Safety and efficacy of tisagenlecleucel (CLTl019) in B-cell acute lymphoblastic leukemia in children and young adults: the French experience. Presented at: Blood; 2019; Orlando, Florida: ASH.
   Google Scholar
• Bader A. Real life experience in the treatment of pediatric, adolescent and young adult ALL patients using commercially available CAR-T cells. Presented at: 1st European CAR T Cell Meeting; 2019.
   Google Scholar
• Grupp S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel Chimeric Antigen Receptor (car) t-cell therapy for relapsed/refractory children and young adults with acute lymphoblastic leukemia (ALL): real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry. Presented at: Blood; 2019; ASH Annual Meeting; December 7–10; Orlando, Florida.
   Google Scholar
• Pasquini M, Hu ZH, Zhang Y. Real world experience of tisagenlecleucel Chimeric Antigen Receptor (CAR) T-cells targeting cd19 in patients with acute lymphoblastic leukemia (all) and diffuse large b-cell lymphoma (dlbcl) using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Presented at: Clinical Lymphoma, Myeloma & Leukemia; 2019. Available from: https://epostersonline.com/soho2019/node/711?view=true. Accessed April 20, 2022.
   Google Scholar
• Wang XJ, Wang YH, Li SCT, et al. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance payer’s perspective. J Med Econ. 2021;24(1):637–653. doi:10.1080/13696998.2021.1922066
   PubMed Web of Science ®Google Scholar
• Nicedsu.org.uk. Nice DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. TSD 19 (nicedsu.org.uk); 2017.
   Google Scholar
• Clinicaltrials.gov. Study of efficacy and safety of CTL019 in Pediatric ALL patients. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02228096. Accessed June 15, 2020.
   Google Scholar
• Clinicaltrials.gov. Phase I/IIA study of cart19 cells for patients with chemotherapy resistant or refractory cd19+ leukemia and lymphoma (pedi cART19). Available from: https://clinicaltrials.gov/ct2/show/NCT01626495. Accessed January 15, 2017.
   Google Scholar
• NICE. Single technology appraisal. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years [ID1167], committee papers; 2018. Available from: https://www.nice.org.uk/guidance/ta554/documents/committee-papers. Accessed June 6, 2020.
   Google Scholar
• CADTH. Canadian Agency for Drugs and Technologies in Health (CADTH) optimal use report. tisagenlecleucel for acute lymphoblastic leukemia: economic review report; 2020. Available from: https://cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-economic-report-pALL-jan2019.pdf. Accessed April 20, 2022.
   Google Scholar
• MSAC. public summary document, tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL); 2019. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/A2B10F9A03293BC8CA2583CF001C7A4D/$File/1519.1%20Final%20updated%20PSD%20Nov%2019_redacted.pdf. Accessed August 21, 2020.
   Google Scholar
• Agency for Care Effectiveness. ACE Clinical Guidance (ACG) process and methods; 2020. Available from: https://www.ace-hta.gov.sg/our-process-and-methods.html. Accessed April 20, 2022.
   Google Scholar
• Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8. doi:10.1186/1478-7547-1-8
   PubMedGoogle Scholar
• Department of Statistics Singapore. Department of Statistics Singapore; 2020. Avaliable from: https://www.singstat.gov.sg/modules/infographics/economy. Accessed April 20, 2022.
   Google Scholar
• MAS. Monetary authority of Singapore. Exchange rates; 2021. Available from: https://eservices.mas.gov.sg/Statistics/msb/ExchangeRates.aspx. Accessed April 20, 2022.
   Google Scholar
• Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer J. 2018;8(9):80. doi:10.1038/s41408-018-0117-0
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi:10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009–2017. doi:10.1016/S0140-6736(10)62002-8
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D, Thomas X, et al. clinician concepts of cure in adult relapsed and refractory Philadelphia-negative b cell precursor acute lymphoblastic leukemia: a delphi study. Adv Ther. 2019;36(4):870–879. doi:10.1007/s12325-019-00910-z
   PubMed Web of Science ®Google Scholar
• Department of Statistics Singapore. complete life tables for Singapore resident population, 2017–2018. Avalibale from: https://www.singstat.gov.sg/publications/population/complete-life-table. Accessed June 12, 2020.
   Google Scholar
• MacArthur AC, Spinelli JJ, Rogers PC, Goddard KJ, Abanto ZU, McBride ML. Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada. Pediatr Blood Cancer. 2007;48(4):460–467. doi:10.1002/pbc.20922
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. pediatric acute lymphoblastic leukemia: version 2.2020; 2019. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed April 20, 2022.
   Google Scholar
• NHS Network Site Specific Group (NSSG). Haematology. myeloid group - FLA-IDA; 2020. Available from: http://nssg.oxford-haematology.org.uk/myeloid/protocols/ML-9-fla-ida.pdf. Accessed April 20, 2022.
   Google Scholar
• Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: children’s oncology group study CCG-1941. J Clin Oncol. 2006;24(19):3150–3156. doi:10.1200/JCO.2005.04.5856
   PubMed Web of Science ®Google Scholar
• Svendsen AL, Feychting M, Klaeboe L, Langmark F, Schuz J. Time trends in the incidence of acute lymphoblastic leukemia among children 1976–2002: a population-based Nordic study. J Pediatr. 2007;151(5):548–550. doi:10.1016/j.jpeds.2007.07.006
   PubMed Web of Science ®Google Scholar
• HSA Product Information. Blincyto. Available from: https://myhealthbox.eu/en/view/3625248/8a63a97851d9c6b3780501cec3e7181a/leaflet. Accessed June 24, 2020.
   Google Scholar
• Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a children’s oncology group study[corrected]. J Clin Oncol. 2008;26(24):3971–3978. doi:10.1200/JCO.2008.16.1414
   PubMed Web of Science ®Google Scholar
• Phua L, Lee S, Ng K, Aziz M. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Serv Res. 2020;20(1). doi:10.21203/rs.2.22855/v1
   PubMed Web of Science ®Google Scholar
• Lee YK, Nam HS, Chuang LH, et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health. 2009;12(8):1187–1193. doi:10.1111/j.1524-4733.2009.00579.x
   PubMed Web of Science ®Google Scholar
• Szende A, Janssen MF, Cabases JM. Self-reported population health: an international perspective based on EQ-5D; 2014: 1–196.
   Google Scholar
• Sung L, Buckstein R, Doyle JJ, Crump M, Detsky AS. Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. Cancer. 2003;97(3):592–600. doi:10.1002/cncr.11098
   PubMed Web of Science ®Google Scholar
• Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1–204. doi:10.3310/hta21070
   PubMed Web of Science ®Google Scholar
• National Cancer Centre Singapore. Cancer incidence in Singapore. Available from: https://www.nccs.com.sg/patient-care/cancer-types/cancer-statistics. Accessed June 12, 2020.
   Google Scholar
• Locatelli F, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120(14):2807–2816. doi:10.1182/blood-2012-02-265884
   PubMed Web of Science ®Google Scholar
• Lin JK, Lerman BJ, Barnes JI, et al. cost effectiveness of chimeric antigen receptor t-cell therapy in relapsed or refractory pediatric b-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192–3202. doi:10.1200/JCO.2018.79.0642
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang J, Hampe M. Cost-effectiveness of tisagenlecleucel in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: a Canadian societal perspective. Value Health. 2018; 21:S43.
   Web of Science ®Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed/refractory b-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719–726. doi:10.1093/jnci/djy193
   PubMedGoogle Scholar
• Wakase S, Teshima T, Zhang J, et al. cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma in Japan. Cell Ther Transpl. 2021;27(6):506e1–506 e10. doi:10.1016/j.jtct.2021.03.005
   Google Scholar
• The York Report. Exploring the assessment and appraisal of regenerative medicines and cell therapy products; 2016. Available from: http://docplayer.net/18693201-Exploring-the-assessment-and-appraisal-of-regenerative-medicines-and-cell-therapy-products.html. Accessed June 6, 2020.
   Google Scholar
• Szende A, Janssen B, Cabases J Self-reported population health: an international perspective based on EQ-5D. Springer; 2014. Avaialbe from: https://link.springer.com/content/pdf/10.1007/978-94-007-7596-1.pdf. Accessed April 20, 2022.
   Google Scholar
• Kelly MJ, Pauker SG, Parsons SK. Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(5):790–797. doi:10.1002/pbc.25451
   PubMed Web of Science ®Google Scholar
• Kuhlen M, Willasch AM, Dalle JH, et al. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. Br J Haematol. 2018;180(1):82–89. doi:10.1111/bjh.14965
   PubMed Web of Science ®Google Scholar